FDA Approves Hizentra® (Immune Globulin Subcutaneous 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP

• Source: finance.yahoo
• 687
• March 20, 2018